Masoud Babaei1, Lina Jansen1, Yesilda Balavarca2, Annika Sjövall3, Amanda Bos4, Tony van de Velde5, Michel Moreau6, Gabriel Liberale6, Ana Filipa Gonçalves7, Maria José Bento7, Cornelia M Ulrich8, Petra Schrotz-King2, Valery Lemmens4, Bengt Glimelius9, Hermann Brenner10. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. 2. Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany. 3. Center for Digestive Diseases, Karolinska Institutet, Sweden. 4. Comprehensive Cancer Organization The Netherlands, Utrecht, The Netherlands; Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. 5. Biometrics Department, the Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Datacenter, Institute Jules Bordet, Bruxelles, Belgium. 7. Portuguese Oncology Institute of Porto, Porto, Portugal. 8. Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany. 9. Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden. 10. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany. Electronic address: h.brenner@dkfz.de.
Abstract
BACKGROUND: Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers. MATERIALS AND METHODS: Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders. RESULTS: A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers. CONCLUSIONS: Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancer patients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers.
BACKGROUND: Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers. MATERIALS AND METHODS: Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders. RESULTS: A total of 16,095 rectal cancerpatients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers. CONCLUSIONS: Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancerpatients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers.
Authors: Anne J Breugom; Marloes Swets; Jean-François Bosset; Laurence Collette; Aldo Sainato; Luca Cionini; Rob Glynne-Jones; Nicholas Counsell; Esther Bastiaannet; Colette B M van den Broek; Gerrit-Jan Liefers; Hein Putter; Cornelis J H van de Velde Journal: Lancet Oncol Date: 2015-01-12 Impact factor: 41.316
Authors: R K S Wong; S Berry; K Spithoff; M Simunovic; K Chan; O Agboola; B Dingle Journal: Clin Oncol (R Coll Radiol) Date: 2010-05 Impact factor: 4.126
Authors: C B M van den Broek; W van Gijn; E Bastiaannet; B Møller; R Johansson; M A G Elferink; A Wibe; L Påhlman; L H Iversen; F Penninckx; V Valentini; C J H van de Velde Journal: Eur J Surg Oncol Date: 2014-10-18 Impact factor: 4.424
Authors: Al B Benson; Tanios Bekaii-Saab; Emily Chan; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Paul F Engstrom; Peter C Enzinger; Marwan G Fakih; Charles S Fuchs; Jean L Grem; Steven Hunt; Lucille A Leong; Edward Lin; Michael G Martin; Kilian Salerno May; Mary F Mulcahy; Kate Murphy; Eric Rohren; David P Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; William Small; Constantinos T Sofocleous; Alan P Venook; Christopher G Willett; Deborah A Freedman-Cass; Kristina M Gregory Journal: J Natl Compr Canc Netw Date: 2012-12-01 Impact factor: 11.908
Authors: Camille Maringe; Sarah Walters; Bernard Rachet; John Butler; Tony Fields; Paul Finan; Roy Maxwell; Bjørn Nedrebø; Lars Påhlman; Annika Sjövall; Allan Spigelman; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Eva Morris; Colleen E McGahan; Elizabeth Tracey; Donna Turner; Michael A Richards; Michel P Coleman Journal: Acta Oncol Date: 2013-04-15 Impact factor: 4.089
Authors: Cornelis J H van de Velde; Petra G Boelens; Josep M Borras; Jan-Willem Coebergh; Andres Cervantes; Lennart Blomqvist; Regina G H Beets-Tan; Colette B M van den Broek; Gina Brown; Eric Van Cutsem; Eloy Espin; Karin Haustermans; Bengt Glimelius; Lene H Iversen; J Han van Krieken; Corrie A M Marijnen; Geoffrey Henning; Jola Gore-Booth; Elisa Meldolesi; Pawel Mroczkowski; Iris Nagtegaal; Peter Naredi; Hector Ortiz; Lars Påhlman; Philip Quirke; Claus Rödel; Arnaud Roth; Harm Rutten; Hans J Schmoll; Jason J Smith; Pieter J Tanis; Claire Taylor; Arne Wibe; Theo Wiggers; Maria A Gambacorta; Cynthia Aristei; Vincenzo Valentini Journal: Eur J Cancer Date: 2013-10-31 Impact factor: 9.162
Authors: Mauro Podda; Patricia Sylla; Gianluca Baiocchi; Michel Adamina; Vanni Agnoletti; Ferdinando Agresta; Luca Ansaloni; Alberto Arezzo; Nicola Avenia; Walter Biffl; Antonio Biondi; Simona Bui; Fabio C Campanile; Paolo Carcoforo; Claudia Commisso; Antonio Crucitti; Nicola De'Angelis; Gian Luigi De'Angelis; Massimo De Filippo; Belinda De Simone; Salomone Di Saverio; Giorgio Ercolani; Gustavo P Fraga; Francesco Gabrielli; Federica Gaiani; Mario Guerrieri; Angelo Guttadauro; Yoram Kluger; Ari K Leppaniemi; Andrea Loffredo; Tiziana Meschi; Ernest E Moore; Monica Ortenzi; Francesco Pata; Dario Parini; Adolfo Pisanu; Gilberto Poggioli; Andrea Polistena; Alessandro Puzziello; Fabio Rondelli; Massimo Sartelli; Neil Smart; Michael E Sugrue; Patricia Tejedor; Marco Vacante; Federico Coccolini; Justin Davies; Fausto Catena Journal: World J Emerg Surg Date: 2021-07-02 Impact factor: 5.469
Authors: Jun Woo Bong; Yeonuk Ju; Jihyun Seo; Jung Ae Lee; Sang Hee Kang; Sun Il Lee; Byung Wook Min Journal: Ann Surg Treat Res Date: 2021-04-29 Impact factor: 1.859